The first treatment based on the Nobel Prize-winning Crispr technology is poised to win FDA approval next month, offering hope to patients and opportunities to investors.
Elizabeth O’Donnell, MD, and Tomasz Beer, MD, FACP, recap key takeaways from the panel and consider the potential of MCED testing in transforming cancer screening and addressing gaps in early detection.
The FDA has delayed its decision on whether to approve Bristol Myers Squibb and 2seventy bio’s CAR-T cell therapy, as it plans to seek further advice from experts.
Christian John Lillis, cofounder and executive director of the Peggy Lillis Foundation for C. Diff Education & Advocacy, explained how FDA-approved microbiome-based therapeutics help to treat and prevent Clostridioides difficile infection.